Copeptin is not useful as a marker of malignant disease in the syndrome of inappropriate antidiuresis
- Winzeler, Bettina 2Department Clinical Research, University of Basel, Basel, Switzerland
- Steinmetz, Michelle 2Department Clinical Research, University of Basel, Basel, Switzerland
- Refardt, Julie 2Department Clinical Research, University of Basel, Basel, Switzerland
- Cesana-Nigro, Nicole 3Department of Endocrinology and Diabetology, Bürgerspital Solothurn, Solothurn, Switzerland
- Popovic, Milica 2Department Clinical Research, University of Basel, Basel, Switzerland
- Fenske, Wiebke 5Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, Germany
- Christ-Crain, Mirjam 2Department Clinical Research, University of Basel, Basel, Switzerland
Published in:
- Endocrine Connections. - Bioscientifica. - 2020, vol. 9, no. 1, p. 20-27
English
Objective
The syndrome of inappropriate antidiuresis (SIAD) is a common condition in hospitalized patients. It is crucial to establish the cause of SIAD, especially in order to exclude underlying malignancy. As malignant SIAD may be due to a paraneoplastic synthesis of arginine vasopressin, we hypothesized that its stable surrogate marker copeptin can be used as a diagnostic tool to differentiate between malignant and non-malignant SIAD.
Methods
Prospective observational study. We analyzed data from 146 SIAD patients of two different cohorts from Switzerland and Germany. Patients were included while presenting at the emergency department and underwent a standardized diagnostic assessment including the measurement of copeptin levels.
Results
Thirty-nine patients (median age: 63 years, 51% female) were diagnosed with cancer-related SIAD and 107 (median age: 73 years, 68% female) with non-malignant SIAD. Serum sodium levels were higher in cancer-related versus non-malignant SIAD: median (IQR) 124 mmol/l (120; 127) versus 120 mmol/l (117; 123) (P <0.001). Median (IQR) copeptin levels of patients with cancer-related SIAD were 11.1 pmol/l (5.2; 37.1) and 10.5 pmol/l (5.2; 25.2) with non-malignant SIAD (P = 0.38). Among different cancer entities, patients suffering from small-cell lung cancer showed the highest copeptin values, but overall no significant difference in copeptin levels between cancer types was observed (P = 0.46).
Conclusions
Copeptin levels are similar in cancer-related and non-malignant SIAD. Therefore, Copeptin does not seem to be suitable as a marker of malignant disease in SIAD.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1530/ec-19-0431
- ISSN 2049-3614
- Persistent URL
- https://folia.unifr.ch/global/documents/109723
Statistics
Document views: 12
File downloads:
- fulltext.pdf: 0